Payment overview · 2025
General Payments
$2,640.78
108 reported records · 24 companies
Healthcare provider profile · identity verified
Steve I Chang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BERLIN, WI · NPI 1295897569
Verified facts
What the public records show
CMS Open Payments records show Steve I Chang, MD received $2,640.78 in general payments during 2025 across 108 reported records.
Novo Nordisk Inc accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Briviact, Eliquis, Gemtesa, Ingrezza, Jardiance, Linzess, Qulipta, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 740 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 740 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $368.16 | 13.9% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $273.06 | 10.3% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $253.97 | 9.6% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $251.69 | 9.5% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $181.91 | 6.9% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.44 | 6.1% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.99 | 5.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.99 | 5.4% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $132.70 | 5.0% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.79 | 4.5% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $91.33 | 3.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $91.12 | 3.5% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$70.16 | 2.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $50.29 | 1.9% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$41.93 | 1.6% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.64 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.96 | 1.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.76 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.61 | 1.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.04 | 1.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.26 | 1.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $25.97 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.99 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.02 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,640.78 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $253.97 | 9 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $229.42 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $209.91 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.18 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $188.09 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $175.61 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $166.98 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $154.36 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $91.33 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.05 | 5 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $70.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.19 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.79 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.79 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 33 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 740 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
740 | 105 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
740 | 105 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1029 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 973 | 174 |
| Furosemide | Furosemide | 969 | 145 |
| Eliquis | Apixaban | 740 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 729 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 721 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 591 | 104 |
| Potassium Chloride | Potassium Chloride | 422 | 81 |
| Sertraline Hcl | Sertraline Hcl | 411 | 64 |
| Gabapentin | Gabapentin | 410 | 100 |
| Lisinopril | Lisinopril | 387 | 64 |
| Losartan Potassium | Losartan Potassium | 377 | 68 |
| Metformin Hcl | Metformin Hcl | 323 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 57 |
| Mirtazapine | Mirtazapine | 300 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 62 |
| Divalproex Sodium | Divalproex Sodium | 269 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 49 |
| Omeprazole | Omeprazole | 261 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 227 | 42 |
| Buspirone Hcl | Buspirone Hcl | 226 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 36 |
| Simvastatin | Simvastatin | 211 | 36 |
| Donepezil Hcl | Donepezil Hcl | 203 | 37 |
| Carvedilol | Carvedilol | 197 | 32 |
| Trazodone Hcl | Trazodone Hcl | 184 | 36 |
| Warfarin Sodium | Warfarin Sodium | 184 | 18 |
| Metolazone | Metolazone | 183 | 41 |
| Midodrine Hcl | Midodrine Hcl | 173 | 41 |
| Xarelto | Rivaroxaban | 168 | 25 |
| Jardiance | Empagliflozin | 164 | 19 |
| Allopurinol | Allopurinol | 163 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 28 |
| Baclofen | Baclofen | 154 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 154 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 148 | 20 |
| Memantine Hcl | Memantine Hcl | 145 | 26 |
| Latanoprost | Latanoprost | 139 | 35 |
| Bumetanide | Bumetanide | 136 | 40 |
| Myrbetriq | Mirabegron | 134 | 22 |
| Levetiracetam | Levetiracetam | 125 | 18 |
| Digoxin | Digoxin | 122 | 23 |
| Spironolactone | Spironolactone | 121 | 21 |
| Montelukast Sodium | Montelukast Sodium | 115 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 21 |
| Tramadol Hcl | Tramadol Hcl | 110 | 39 |
| Famotidine | Famotidine | 107 | 27 |
| Lorazepam | Lorazepam | 107 | 26 |
| Prednisone | Prednisone | 104 | 30 |
| Finasteride | Finasteride | 99 | 21 |
| Pregabalin | Pregabalin | 99 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 38 |
| Alendronate Sodium | Alendronate Sodium | 79 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 16 |
| Farxiga | Dapagliflozin Propanediol | 65 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 39 |
| Aripiprazole | Aripiprazole | 57 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 44 |
| Glipizide | Glipizide | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 29 |
| Lamotrigine | Lamotrigine | 51 | 12 |
| Linzess | Linaclotide | 48 | suppressed |
| Timolol Maleate | Timolol Maleate | 48 | 13 |
| Atenolol | Atenolol | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 43 | 42 |
| Briviact | Brivaracetam | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 41 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Cephalexin | Cephalexin | 38 | 26 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Ingrezza | Valbenazine Tosylate | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Trospium Chloride | Trospium Chloride | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 13 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 13 |
| Chlorthalidone | Chlorthalidone | 21 | 11 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Torsemide | Torsemide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Alphagan P | Brimonidine Tartrate | 16 | suppressed |
| Brinzolamide | Brinzolamide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Zonisade | Zonisamide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 12 |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,640.78 · 108 records | Novo Nordisk Inc | ABRYSVO, ACTHAR, AIRSUPRA, AMYVID, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Briviact, CAMZYOS, CAPLYTA, COMIRNATY, CREON, ELIQUIS, GEMTESA, INGREZZA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, NOURIANZ, NURTEC ODT, NUZYRA, Nayzilam, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VALTOCO, VRAYLAR, VYNDAMAX, WATCHMAN Access System, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error